Content about upsher

May 6, 2013

There is no substitute for the face-to-face counsel of the pharmacist in improving patient adherence — and he’s got the data to prove it. That’s the message Thrifty White president and CEO Bob Narveson had for DSNTV in part two of a frank and broad-ranging interview about the state of the industry, the role community pharmacy can play in healthcare reform and the results of an exciting new study that validates the role companies like his can play to innovate patient care, improve outcomes and lower healthcare costs.

FARGO, N.D. — There is no substitute for the face-to-face counsel of the pharmacist in improving patient adherence — and he’s got the data to prove it. That’s the message Thrifty White president and CEO Bob Narveson had for DSNTV in part two of a frank and broad-ranging interview about the state of the industry, the role community pharmacy can play in healthcare reform and the results of an exciting new study that validates the role companies like his can play to innovate patient care, improve outcomes and lower healthcare costs.

April 16, 2013

This is going to be a big year for community pharmacy, said Thrifty White president and CEO Bob Narveson, as the nation reaches full implementation of the Patient Protection and Affordable Care Act in 2014. “But to be successful, we are going to have to maintain access to those patients,” Narveson told DSNTV last month in a frank and broad-ranging discussion about the state of the industry, the role community pharmacy can play in healthcare reform, and how NACDS member companies like his own are innovating patient care, driving improved outcomes and lowering costs.

FARGO, N.D. — This is going to be a big year for community pharmacy, said Thrifty White president and CEO Bob Narveson, as the nation reaches full implementation of the Patient Protection and Affordable Care Act in 2014.

March 12, 2014

Upsher-Smith has received approval from the Food and Drug Administration for Qudexy XR (topiramate) extended-release capsules, a once-daily, broad-spectrum antiepileptic drug specifically engineered to deliver a smooth pharmacokinetic profile.

MAPLE GROVE, Minn. — Upsher-Smith has received approval from the Food and Drug Administration for Qudexy XR (topiramate) extended-release capsules, a once-daily, broad-spectrum antiepileptic drug specifically engineered to deliver a smooth pharmacokinetic profile.

Qudexy XR will be available to patients in second quarter 2014.